CDK2 and breast cancer: The drug response test using PDOs further validated that high MITH was an indicator for CDK4/6 inhibitor resistance in HR+ breast cancers and CDK2/4/6 inhibitor may be an effective option for the patients with high-MITH HR+ breast cancer.